Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-07-09

Clinical Trial Update: Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating whether omalizumab improves the asthmatic response to rhinovirus infection; the study has completed and results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Xolair (omalizumab)

Snippet

Sponsor: University of Virginia | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2018-07-09